Hypertension (HTN) is one of the most prevalent diseases worldwide and is among the most
important risk factors for cardiovascular and cerebrovascular complications. It is currently …

Endothelin (ET) peptides and their receptors are intimately involved in the physiological
control of systemic blood pressure and body Na homeostasis, exerting these effects through …

Endothelin-1 (ET-1), a vasoactive peptide, is believed to contribute to the pathogenesis of
vascular abnormalities such as hypertension, atherosclerosis, hypertrophy and restenosis …

As our understanding of the underlying aetiology of hypertension is far from adequate, over
90% of patients with hypertension receive a diagnosis of essential hypertension. This non …

Since its discovery in 1988 as an endothelial cell-derived peptide that exerts the most potent
vasoconstriction of any known endogenous compound, endothelin (ET) has emerged as an …

Development and progression of end-organ damage in hypertension have been associated
with increased oxidative stress. Superoxide anion accumulation has been reported in …

Aim: Recent experimental and human studies have shown that hyperuricemia is associated
with hypertension and cardiovascular diseases. Elevated levels of endothelin‐1 (ET‐1) has …

Endothelin-1,(ET-1, EDN1) is an endogenous polypeptide which demonstrates dominant
vasoconstriction activity and mitogenic effect. It has positive inotropic and chronotropic …

Abstract Endothelin-1 (ET-1) is the most potent vasoconstrictor by binding to endothelin
receptors (ET AR) in vascular smooth muscle cells (VSMCs). The complex of angiotensin II …

1 Although statins have been reported to inhibit the prepro‐endothelin‐1 (ET‐1) gene
transcription in endothelial cells, their effects on the vascular function of ET‐1 have not been …